Loading…
BioNTech SE is projected to rise to $117.53 by 2027, a +27% move from its current price of $92.85. BNTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $91.63 | $92.88 | $94.15 | +0.03% |
| Aug 2 | $91.14 | $92.91 | $94.71 | +0.06% |
| Aug 3 | $90.78 | $92.94 | $95.14 | +0.09% |
| Aug 4 | $90.48 | $92.96 | $95.52 | +0.12% |
| Aug 5 | $90.22 | $92.99 | $95.86 | +0.15% |
| Aug 6 | $89.98 | $93.02 | $96.16 | +0.19% |
| Aug 7 | $89.77 | $93.05 | $96.45 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $89.77 | $93.05 | $96.45 | +0.22% |
| Week 2 | $88.64 | $93.25 | $98.10 | +0.43% |
| Week 3 | $87.83 | $93.45 | $99.44 | +0.65% |
| Week 4 | $87.17 | $93.66 | $100.62 | +0.87% |
| Week 5 | $86.63 | $93.86 | $101.70 | +1.09% |
| Week 6 | $86.15 | $94.06 | $102.70 | +1.31% |
| Week 7 | $85.73 | $94.27 | $103.65 | +1.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer.
In addition, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
BioNTech SE (BNTX) is a healthcare stock with a current price of $91.48 and a market capitalization of $23.13B, ranking 533. The current price and market position provide a baseline for the longer-term outlook shown in the forecast table. The year-by-year forecast outlines a path from a neutral start in 2026 to a clearly bullish trajectory through 2050, with higher expected average prices and sizable ROIs in later years.
A major floor 8.4% below — a decisive break under it would weaken the trend.
The nearest floor, 3.8% below — buyers have tended to step in here.
The nearest ceiling, 5.1% above — a clean break opens room to run.
A major ceiling 20.2% above — clearing it would confirm fresh momentum.
Key BNTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BNTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $91.73 | Buy | $92.29 | Buy |
| MA 10 | $91.85 | Buy | $92.04 | Buy |
| MA 20 | $92.32 | Buy | $91.95 | Buy |
| MA 50 | $91.28 | Buy | $92.38 | Buy |
| MA 100 | $92.98 | Sell | $94.19 | Sell |
| MA 200 | $98.27 | Sell | $97.12 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.26 | Neutral |
| Stoch RSI (14) | 97.00 | Sell |
| CCI (20) | 29.65 | Neutral |
| Williams %R (14) | -2.76 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 2.71 | Buy |
| Bollinger %B (20,2) | 0.58 | Neutral |
| Stochastic %K (14) | 97.24 | Sell |
| TRIX (15) | 0.01 | Buy |
| Awesome (5,34) | -0.13 | Sell |
| Ultimate (7,14,28) | 54.17 | Neutral |
| Momentum (10) | 1.29 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 92.61 | Buy |
| ADX (14) | 7.08 | Neutral |
| ATR (14) | 1.07 | Info |
The 30-day technical picture is NEUTRAL. RSI14 sits at 50, and the short-term moving averages are $91.38 for the SMA50 and $98.81 for the SMA200, indicating a balanced view versus trend. Support is seen at $85.50 and resistance at $97.54, with the 30-day price range between $82.84 and $101.02.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $83.89 | $92.85 | $120.65 | 0% | Neutral | |
| $96.36 | $117.53 | $149.78 | +27% | Bullish | |
| $113.24 | $140.74 | $184.29 | +52% | Bullish | |
| $125.07 | $157.86 | $211.16 | +70% | Bullish | |
| $123.62 | $158.15 | $215.39 | +70% | Bullish | |
| $136.15 | $176.32 | $243.95 | +90% | Bullish | |
| $151.77 | $198.78 | $278.96 | +114% | Bullish | |
| $166.26 | $220.06 | $312.84 | +137% | Bullish | |
| $195.09 | $260.79 | $375.20 | +181% | Bullish | |
| $207.08 | $279.45 | $406.52 | +201% | Bullish | |
| $306.47 | $431.38 | $657.73 | +365% | Bullish | |
| $495.21 | $747.62 | $1,222.04 | +705% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $83.89 | $92.85 | $108.21 | +0.00% |
| August 2026 | $82.30 | $95.97 | $114.04 | +3.36% |
| September 2026 | $81.44 | $95.50 | $114.55 | -0.48% |
| October 2026 | $80.25 | $94.54 | $114.25 | -1.00% |
| November 2026 | $81.90 | $96.85 | $117.74 | +2.44% |
| December 2026 | $83.18 | $98.71 | $120.65 | +1.92% |
Click any year to see its month-by-month BNTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
BioNTech SE's 2026 outlook centres on $92.85, within a $83.89 to $120.65 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, BNTX could reach as high as $149.78, with a base case around $117.53 and support toward $96.36 — roughly +27% from $92.85. Momentum favours further upside here.
Expect BNTX to range from $113.24 to $184.29 through 2028. The $140.74 average target implies a +52% move from current prices. That is up +20% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The BNTX price prediction for 2029 points to an average of $157.86 (low $125.07, high $211.16) — a potential gain of +70% on today's $92.85. Momentum favours further upside here.
In 2030, BNTX is projected to trade between $123.62 and $215.39, averaging $158.15 — a potential gain of +70% from today's $92.85. That is up 0% on the projected 2029 average. Buyers look set to stay in control over this stretch.
BioNTech SE's 2031 outlook centres on $176.32, within a $136.15 to $243.95 range. That is up +11% on the projected 2030 average. That marks a +90% change versus current levels. Momentum favours further upside here.
By 2032, BNTX could reach as high as $278.96, with a base case around $198.78 and support toward $151.77 — roughly +114% from $92.85. Buyers look set to stay in control over this stretch.
Expect BNTX to range from $166.26 to $312.84 through 2033. The $220.06 average target implies a +137% move from current prices. That is up +11% on the projected 2032 average. Momentum favours further upside here.
The BNTX price prediction for 2034 points to an average of $260.79 (low $195.09, high $375.20) — a potential gain of +181% on today's $92.85. Buyers look set to stay in control over this stretch.
In 2035, BNTX is projected to trade between $207.08 and $406.52, averaging $279.45 — a potential gain of +201% from today's $92.85. That is up +7% on the projected 2034 average. Momentum favours further upside here.
BioNTech SE's 2040 outlook centres on $431.38, within a $306.47 to $657.73 range. That is up +54% on the projected 2035 average. That marks a +365% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, BNTX could reach as high as $1,222.04, with a base case around $747.62 and support toward $495.21 — roughly +705% from $92.85. Momentum favours further upside here.
Investing $1,000 in BNTX today (≈ 10.770059 BNTX) could be worth
$8,051.94
+$7,051.94 (+705%) by 2050 · US Dollar
Based on the average projected BNTX price of $747.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BNTXwould be worth at today's price.
$1,000 invested in BNTX on Jul 30, 2025 (≈ 9.086778 BNTX) would be worth
$843.71
-$156.29 (-15.6%) today · 0.84× · US Dollar
Based on a BNTX entry price of $110.05 vs. today's $92.85.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $92.06 | $1,008.58 | +0.9% |
| 1 month ago | $93.05 | $997.85 | -0.2% |
| 3 months ago | $97.54 | $951.92 | -4.8% |
| 6 months ago | $113.75 | $816.26 | -18.4% |
| 1 year ago | $110.05 | $843.71 | -15.6% |
| All time (5.0y) ago | $340.21 | $272.92 | -72.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BNTX forecast.
Our base-case forecast reaches $190.00 around 2032.
Implied market cap at $190.00: $48.05B
Looking further out, the multi-year forecast shows a bullish trajectory from 2027 onward. The 2027 average price is $115.57 with an ROI of 26.3% (sentiment BULLISH). In 2028 the average rises to $137.76 (ROI 50.6%), and in 2029 to $151.50 (ROI 65.6%), with 2030 averaging $152.59 (ROI 66.8%).
The gains continue with 2031 at $170.79 (ROI 86.7%), 2032 at $188.75 (ROI 106.3%), 2033 at $208.84 (ROI 128.3%), 2034 at $249.53 (ROI 172.8%), and 2035 at $264.02 (ROI 188.6%). The forecast then shows a substantial rise to $407.26 on average in 2040 (ROI 345.2%) and $687.99 in 2050 (ROI 652.1%), all with a bullish sentiment. These are estimates, not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $152.59 with a max of $207.93, a min of $119.22, and an ROI of 66.8%; sentiment is BULLISH.
Forecasts indicate a bullish path starting in 2027 with rising average prices and strong ROIs, following a neutral start in 2026.
Yes—the forecast for 2028 shows a maximum of $180.54.
RSI(14) is 50, SMA50 is $91.38, SMA200 is $98.81, with support at $85.50 and resistance at $97.54. The 30-day range is $82.84–$101.02, and annualized volatility is 30%.
BioNTech SE Community Discussion
0Share your BioNTech SE price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.